The Dental Management of Patients at Risk of Medication-Related Osteonecrosis of the Jaw: New Paradigm of Primary Prevention

Table 6

Drug suspension for non-cancer patients; it must be agreed upon with the prescriber and performed according to the table.

Drug holiday in non-cancer patients
Active pharmaceutical ingredient	Last administration	Therapy resumption
(AR)	1 week before	4–6 weeks after
Denosumab (AR)	No

by more than three years or for less than three years and in the presence of other systemic risk factors; suspension is not needed thanks to the latency between drug administrations. It is useful to perform invasive procedures between the first and the third month from the last administration, so as to ensure an adequate period for healing before the next dose.